Corvus Pharmaceuticals (NASDAQ:CRVS) Downgraded by StockNews.com

StockNews.com cut shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Free Report) from a hold rating to a sell rating in a report released on Thursday. Several other research firms have also recently weighed in on CRVS. Cantor Fitzgerald lifted their price objective on Corvus Pharmaceuticals from $2.00 to $4.00 in a report on Tuesday, May 9th. […]

Related Keywords

,Corvus Pharmaceuticals Stock Performance ,Renaissance Technologies ,Acadian Asset Management ,Corvus Pharmaceuticals Company Profile ,Morgan Stanley ,Nasdaq ,News Ratings For Corvus Pharmaceuticals Daily ,Corvus Pharmaceuticals Inc ,Corvus Pharmaceuticals ,Vanguard Group Inc ,Cantor Fitzgerald ,Hedge Funds Weigh In On Corvus Pharmaceuticals ,Free Report ,Get Free Report ,Street Corp ,Asset Management ,Corvus Pharmaceuticals Daily ,Nasdaq Crvs ,Ccrvs ,Medical ,Downgrade ,Stocknews Com ,